Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141672 · ClinicalTrials.gov registry record · Phase 2
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
A Phase 2 study, sponsored by Aurinia Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 265
- Enrollment target
NCT02141672 is a Phase 2 study that has completed, run by Aurinia Pharmaceuticals. The registered enrollment target is 265 participants.
The verdict
NCT02141672, a Phase 2 study, has completed, sponsored by Aurinia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 265 participants
- Enrollment target
Study Summary
To assess the efficacy of 2 doses of voclosporin compared to placebo in achieving complete remission after 24 weeks of therapy in subjects with active lupus nephritis.
Interventions
- DRUG Placebo
- DRUG Voclosporin High Dose
- DRUG Voclosporin Low Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2014-06 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02141672
The ClinicalTrials.gov registry entry for NCT02141672 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aurinia Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02141672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02141672 about?
NCT02141672 is a clinical study titled "AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)". To assess the efficacy of 2 doses of voclosporin compared to placebo in achieving complete remission after 24 weeks of therapy in subjects with active lupus nephritis.
What is the current status of trial NCT02141672?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 265 participants. The study started on 2014-06. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02141672?
The interventions under investigation include: Placebo (DRUG), Voclosporin High Dose (DRUG), Voclosporin Low Dose (DRUG).
Who is sponsoring clinical trial NCT02141672?
This trial is sponsored by Aurinia Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.